Please provide your email address to receive an email when new articles are posted on . Cannabidiol treatment was associated with median reduction of 67% to 99% in focal aware seizures. All ...

Please provide your email address to receive an email when new articles are posted on . Seizure freedom was observed by 12 months and continued past 48 months of the open-label extension. Long-term ...

A new drug candidate has shown impressive results in a mid-stage clinical trial for drug-resistant epilepsy, raising hopes for patients who continue to suffer seizures despite being on multiple ...

Los Angeles — Only about 27% of patients newly diagnosed with focal epilepsy are seizure-free on initial anti-seizure medications (ASMs), new research suggested. This is sobering information to pass ...

Longitudinal data suggested that treatment-resistant focal epilepsy may improve over time. Nearly 70% had reduced seizure frequency and some patients achieved seizure freedom. Improvement was not ...

Nearly 70% of patients with focal treatment-resistant epilepsy (FTRE) experience fewer seizures over time, new results of a multicenter study showed. However, the improvements occurred independent of ...

Certain common genetic changes might make some people with focal epilepsy less responsive to seizure medications, finds a new global study led by researchers at UCL and UTHealth Houston. Focal ...

About one-third of patients with focal epilepsy, a common form of the neurological disorder, are believed to respond poorly to available therapies. Yet they too may eventually see improvement, if not ...

SK Biopharmaceutical’s Xcopri (cenobamate) met the bar in a phase 3 trial that could support the company’s ambitions of building a blockbuster with an expansion into another seizures subtype. Now, ...

About 60-70% of focal epilepsy patients achieve seizure control with first-line antiseizure medications (ASMs). Lamotrigine and levetiracetam demonstrate high efficacy and tolerability for seizure ...